Trials / Completed
CompletedNCT05687071
A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
A Multicenter, Open-label, Uncontrolled, Long-term Trial to Assess the Safety and Efficacy of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Open-label Study to assess the safety and efficacy of ETC-1002 at 180 mg administered for 52 weeks in patients with hyper-LDL cholesterolemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 180mg of ETC-1002(bempedoic acid) | 180mg, tablet, once daily, for 52 weeks |
Timeline
- Start date
- 2023-02-27
- Primary completion
- 2024-10-05
- Completion
- 2024-11-02
- First posted
- 2023-01-17
- Last updated
- 2026-02-20
- Results posted
- 2026-02-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05687071. Inclusion in this directory is not an endorsement.